Case Challenge: Incorporate Real-World Evidence in the Management of Hormone Receptor-Positive Metastatic Breast Cancer

The use of real-world data (RWD) to generate real-world evidence (RWE) that reflects the complexity of usual treatment patterns of oncology care and clinical outcomes, and represents a broader spectrum of patients, can provide treatment benefit estimates outside the well-defined framework of trial settings. The potential for RWE is particularly significant in the oncology setting, where combination therapy offers great benefits for patients. Cyclin-dependent kinase (CDK) 4 and 6 inhibitors in combination with endocrine therapy (ET) have emerged as a standard-of-care treatment for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC), and RWE, when effectively deployed, can help determine treatment effects in the real world.

In this CME Outfitters BriefCase, expert faculty discuss the challenges and nuances of a case scenario as well as practical strategies for incorporating RWE into daily clinical practice in MBC.

At the end of this CE activity, participants should be able to:
-Assess evidence on real-world, clinical experience for CDK 4/6 inhibitors in MBC.
-Integrate RWE into daily practice and decision-making in the MBC setting.